Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.
European Commission approves a new 7.2 mg once weekly maintenance dose of Wegovy for obesity treatment in adults.
The higher Wegovy dose expands Novo Nordisk’s CPSE:NOVO B obesity treatment options within the EU.
The decision provides physicians and patients with an additional therapeutic choice in the GLP 1 weight loss segment.
Novo Nordisk, best known for its diabetes and obesity drugs, now has a broader Wegovy dosing range in Europe with the 7.2 mg maintenance option. For investors, this sits within a wider shift in which obesity care has become a key focus area for large pharma groups, as demand for GLP 1 based weight loss treatments attracts significant attention from payers, regulators and patients.
From here, the questions for investors are less about the headline approval and more about real world adoption, pricing, supply and reimbursement across different EU markets. As competitors work on rival obesity therapies, this additional Wegovy dose could influence how physicians tailor treatment plans and how payers assess the role of GLP 1 drugs in longer term obesity management.
Stay updated on the most important news stories for Novo Nordisk by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Novo Nordisk.
CPSE:NOVO B Earnings & Revenue Growth as at Feb 2026
We’ve flagged 5 risks for Novo Nordisk. See which could impact your investment.
✅ Price vs Analyst Target: At DKK307.4 versus a consensus target of DKK376.6, Novo Nordisk trades about 18% below analyst expectations.
✅ Simply Wall St Valuation: Simply Wall St estimates the shares are trading 65.8% below their Fair Value, flagged as undervalued.
❌ Recent Momentum: The 30 day return of roughly 0.2% decline suggests the share price has been soft recently despite the Wegovy news.
There is only one way to know the right time to buy, sell or hold Novo Nordisk. Head to the Simply Wall St company report for the latest analysis of Novo Nordisk’s Fair Value.
📊 The higher Wegovy dose broadens the obesity offering, which may reinforce Novo Nordisk’s role in GLP 1 treatments if uptake and reimbursement are supportive.
📊 Watch how obesity care contributes to revenue, any capacity or supply commentary, and how the current P/E of about 13.3 compares with the Pharmaceuticals industry average of 13.5.
⚠️ Regulatory, reimbursement and competitive pressures in obesity care, together with flagged company risks, could affect how much value this new dose ultimately adds.
For the full picture including more risks and rewards, check out the complete Novo Nordisk analysis. Alternatively, you can visit the community page for Novo Nordisk to see how other investors believe this latest news will impact the company’s narrative.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NOVO-B.CO.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com